All In Biotech

NDA 214998 · Bristol

Camzyos

Mavacamten · Oral · Cardiac Myosin Inhibitor

NovelBreakthrough therapyOrphan

CDER novel approval, Apr 28, 2022: To treat certain classes of obstructive hypertrophic cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Apr 28, 2022

Approved uses

4

Original approval plus efficacy supplements

Registered trials

26

8 Phase 3, 12 recruiting

FAERS reports

6,048

2,643 serious, 164 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF HEART FAILURE CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction [see Warnings and Precautions (5.1) ] . Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt CAMZYOS if LVEF is <50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ] . Concomitant use of CAMZYOS with certain cytochrome P450 inhibitors or discontinuation of certain cytochrome P450 inducers may increase the risk of heart failure due to systolic dysfunction; therefore, the use of CAMZYOS is contraindicated with the following [see Contraindications (4) and Warnings and Precautions (5.2) ] : • Strong CYP2C19...

What it is approved for

From the label in effect Sep 30, 2026.

CAMZYOS is indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms . CAMZYOS is a cardiac myosin inhibitor indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. ( 1 )

Mechanism: Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. Mavacamten shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In HCM patients, myosin inhibition with mavacamten reduces dynamic LVOT...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • CAMZYOS · MAVACAMTEN 2.5MG · CAPSULE, ORAL · Prescription
  • CAMZYOS · MAVACAMTEN 15MG · CAPSULE, ORAL · Prescription
  • CAMZYOS · MAVACAMTEN 5MG · CAPSULE, ORAL · Prescription
  • CAMZYOS · MAVACAMTEN 1MG · CAPSULE, ORAL · Prescription
  • CAMZYOS · MAVACAMTEN 10MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mavacamten" as an intervention, any sponsor and status, largest first.

All 26 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue442
  • dyspnoea427
  • atrial fibrillation370
  • product dose omission issue362
  • dizziness353
  • product use issue268
  • off label use230
  • ejection fraction decreased224
  • therapy interrupted196
  • chest pain194
  • palpitations182
  • headache174

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2022390
2023825
20241,052
20251,458
20262,323

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Camzyos (Mavacamten)

2024 spending

$291M

Beneficiaries

4,490

35,896 claims

Per beneficiary

$64,772

$272.20 per unit

View as table
YearSpending
2020$0
2021$0
2022$8,095,504
2023$105,090,144
2024$290,825,667

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 62 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.